Latest Pharma Insights
Boston Scientific Halts Enroute TCAR Systems Over Arterial Sheath Issue
Boston Scientific is telling customers to stop using Enroute Transcarotid Neuroprotection System and Enroute Transcarotid Neuroprotection System Plus. The devices, which help prevent stroke during treatment of carotid artery disease, may come apart during use.
Medtech Insight - July 27, 2026
Boston Scientific is telling customers to stop using Enroute Transcarotid Neuroprotection System and Enroute Transcarotid Neuroprotection System Plus. The devices, which help prevent stroke during treatment of carotid artery disease, may come apart during use.
Medtech Insight - July 27, 2026
Finance Watch: Scribe Launches IPO, Oak Hill Going Public Via SPAC Merger
Public Company Edition: Scribe Therapeutics grossed $128.7m in the 14th biopharma IPO in the US in 2026, while Oak Hill Bio will go public by merging with RA Capital’s recent SPAC. Also, Dyne closed a $431.4m follow-on offering and Entra Bio raised $275m in a private placement.
Scrip - July 27, 2026
Public Company Edition: Scribe Therapeutics grossed $128.7m in the 14th biopharma IPO in the US in 2026, while Oak Hill Bio will go public by merging with RA Capital’s recent SPAC. Also, Dyne closed a $431.4m follow-on offering and Entra Bio raised $275m in a private placement.
Scrip - July 27, 2026
MapLight’s ZEPHYR Trial Hits Endpoints In Schizophrenia, But Investors Want To See More
The company reported cognitive improvement in the pivotal Phase II trial of ML-007C-MA and plans a second study in schizophrenia, while a Phase II trial in Alzheimer’s psychosis is ongoing.
Scrip - July 27, 2026
The company reported cognitive improvement in the pivotal Phase II trial of ML-007C-MA and plans a second study in schizophrenia, while a Phase II trial in Alzheimer’s psychosis is ongoing.
Scrip - July 27, 2026
With Forte, Argenx Returns To Pipeline-In-A-Product Playbook
The company made its biggest acquisition to date with the acquisition of Forte, which brings argenx a future pipeline pillar to lean on beyond Vyvgart and empasiprubart.
Scrip - July 27, 2026
The company made its biggest acquisition to date with the acquisition of Forte, which brings argenx a future pipeline pillar to lean on beyond Vyvgart and empasiprubart.
Scrip - July 27, 2026
FDA Approves Colorectal Cancer Blood Test From Freenome And Abbott
The US Food and Drug Administration has approved SimpleScreen CRC, a blood-based colorectal cancer screening test developed by Freenome that Abbott will exclusively commercialize in the US for average-risk adults aged 45 and older. The test detects cell-free DNA signals linked to colorectal cancer.
Medtech Insight - July 27, 2026
The US Food and Drug Administration has approved SimpleScreen CRC, a blood-based colorectal cancer screening test developed by Freenome that Abbott will exclusively commercialize in the US for average-risk adults aged 45 and older. The test detects cell-free DNA signals linked to colorectal cancer.
Medtech Insight - July 27, 2026
Women’s Oncology Market Expected To Reach $110Bn By 2030, Gynecologic Cancers Remain Underfunded
A new PwC report finds women's oncology heading toward $110bn by 2030, yet ovarian and endometrial cancers receive a fraction of breast cancer's NIH funding. Liquid biopsy, AI screening tools, and $6.5bn in private investment aim to close the gap.
Medtech Insight - July 27, 2026
A new PwC report finds women's oncology heading toward $110bn by 2030, yet ovarian and endometrial cancers receive a fraction of breast cancer's NIH funding. Liquid biopsy, AI screening tools, and $6.5bn in private investment aim to close the gap.
Medtech Insight - July 27, 2026
AstraZeneca’s New Breast Cancer Drug Could Be Test Case For MFN Pricing
CEO Pascal Soriot said demands for price rises in Europe were “not unreasonable” as the company kept up its healthy growth in the second quarter.
Scrip - July 27, 2026
CEO Pascal Soriot said demands for price rises in Europe were “not unreasonable” as the company kept up its healthy growth in the second quarter.
Scrip - July 27, 2026
Peer Groups, Not Performance: What Really Drives Large Pharma CEO Pay
CEOs of $10bn–$40bn pharma companies averaged $14.9m in 2025, a 36% discount to the $23.1m big pharma mean. But strip out the non-US firms and the gap nearly closes: the discount is mostly geography, with US chiefs paid up to four times their Japanese and European peers at similar-sized companies.
In Vivo - July 27, 2026
CEOs of $10bn–$40bn pharma companies averaged $14.9m in 2025, a 36% discount to the $23.1m big pharma mean. But strip out the non-US firms and the gap nearly closes: the discount is mostly geography, with US chiefs paid up to four times their Japanese and European peers at similar-sized companies.
In Vivo - July 27, 2026
German Medtech Innovation Decision Signals A Crack In Industry-Government ‘Dialog’
Germany’s medtech industry said it is frustrated by outgoing health minister Warken’s last-minute decision to limit temporary reimbursement and access for new diagnostic and treatment methods (NUB). Spectaris’ medtech head Marcus Kuhlmann criticized the purely money saving initiative.
Medtech Insight - July 27, 2026
Germany’s medtech industry said it is frustrated by outgoing health minister Warken’s last-minute decision to limit temporary reimbursement and access for new diagnostic and treatment methods (NUB). Spectaris’ medtech head Marcus Kuhlmann criticized the purely money saving initiative.
Medtech Insight - July 27, 2026
Reckitt Taps Durex Brand Equity For OTC Sildenafil Launch
As the OTC ED shelf continues to grow, Reckitt is wagering that the Durex name gives it a differentiation rivals cannot easily replicate.
HBW Insight - July 27, 2026
As the OTC ED shelf continues to grow, Reckitt is wagering that the Durex name gives it a differentiation rivals cannot easily replicate.
HBW Insight - July 27, 2026
WHO Names First Medtech Regulators Ready For Listed Authority Status
The World Health Organization is expanding its framework for recognizing trusted regulators into medtech, which it hopes will foster global regulatory cooperation.
Medtech Insight - July 27, 2026
The World Health Organization is expanding its framework for recognizing trusted regulators into medtech, which it hopes will foster global regulatory cooperation.
Medtech Insight - July 27, 2026
‘Not New Anymore’: EMA Moves Biosimilars Closer To Generic-Drug Review Model
As confidence in biosimilars grows, the European Medicines Agency is testing whether less complex marketing applications for such products can be reviewed with fewer regulatory resources, potentially freeing up assessment teams for other medicines.
Generics Bulletin - July 27, 2026
As confidence in biosimilars grows, the European Medicines Agency is testing whether less complex marketing applications for such products can be reviewed with fewer regulatory resources, potentially freeing up assessment teams for other medicines.
Generics Bulletin - July 27, 2026
Dr Reddy’s Semaglutide Woes Ripple Through Partners, CEO Vows Comeback
With "tens of partners" globally, Dr Reddy’s semaglutide supply challenges could potentially have a wider impact if the firm isn’t back in the market by November as anticipated. Partner Aspen has already flagged delays, and a Sandoz Canada supply commitment also hangs on a timely restart.
Generics Bulletin - July 27, 2026
With "tens of partners" globally, Dr Reddy’s semaglutide supply challenges could potentially have a wider impact if the firm isn’t back in the market by November as anticipated. Partner Aspen has already flagged delays, and a Sandoz Canada supply commitment also hangs on a timely restart.
Generics Bulletin - July 27, 2026
Zevra Europe Entry Plans For Neimann-Pick Drug Put On Hold
The US firm is appealing a CHMP negative opinion on its Niemann-Pick disease type C therapy Meplyffa, stalling having hit a stumbling block in its efforts to enter a market which is larger than the US, where the ultra-rare lysosomal storage disorder drug is already approved.
Scrip - July 27, 2026
The US firm is appealing a CHMP negative opinion on its Niemann-Pick disease type C therapy Meplyffa, stalling having hit a stumbling block in its efforts to enter a market which is larger than the US, where the ultra-rare lysosomal storage disorder drug is already approved.
Scrip - July 27, 2026
Acute Care AI Pioneer Viz.ai Takes First Step Into Chronic Brain Disease
Viz.ai is expanding beyond acute care into neurodegenerative disease, partnering with Cortechs.ai to bring quantitative brain MRI analysis into its 2,000-hospital network — with MS as the entry point and broader ambitions to follow.
Medtech Insight - July 27, 2026
Viz.ai is expanding beyond acute care into neurodegenerative disease, partnering with Cortechs.ai to bring quantitative brain MRI analysis into its 2,000-hospital network — with MS as the entry point and broader ambitions to follow.
Medtech Insight - July 27, 2026
Niagen Bioscience Adds External Research Chief
Abhijit Kale oversees firm’s network of academic and clinical research collaborations while helping shape scientific research strategy.
HBW Insight - July 27, 2026
Abhijit Kale oversees firm’s network of academic and clinical research collaborations while helping shape scientific research strategy.
HBW Insight - July 27, 2026
The Eyes Have It! FDA Finally Approves Outlook’s Ophthalmic Bevacizumab
Outlook Therapeutics has set out initial launch plans for its Lytenava ophthalmic bevacizumab product after finally winning approval from the US FDA.
Generics Bulletin - July 27, 2026
Outlook Therapeutics has set out initial launch plans for its Lytenava ophthalmic bevacizumab product after finally winning approval from the US FDA.
Generics Bulletin - July 27, 2026
AstraZeneca Trial Wobbles Continue With Claudin 18.2 ADC Hit And Miss
A split CLARITY-Gastric01 readout gives AstraZeneca the first survival win for a CLDN18.2 ADC, but the PFS miss leaves room for rivals closing in on the same indication.
Scrip - July 27, 2026
A split CLARITY-Gastric01 readout gives AstraZeneca the first survival win for a CLDN18.2 ADC, but the PFS miss leaves room for rivals closing in on the same indication.
Scrip - July 27, 2026
Par Seizes First-Mover Advantage In Janumet XR Generics
Par Health has launched the first and currently only US Food and Drug Administration-approved generic version of Merck & Co’s Janumet XR (sitagliptin/metformin hydrochloride) extended-release tablets in the US, opening generic competition for the extended-release diabetes therapy shortly after agree
Generics Bulletin - July 27, 2026
Par Health has launched the first and currently only US Food and Drug Administration-approved generic version of Merck & Co’s Janumet XR (sitagliptin/metformin hydrochloride) extended-release tablets in the US, opening generic competition for the extended-release diabetes therapy shortly after agree
Generics Bulletin - July 27, 2026
Argenx To Buy Forte Biosciences For $2.2bn, Adds Clinical-Stage CD122 Autoimmune Asset
Argenx's $2.2bn acquisition of Forte Biosciences adds anti-CD122 antibody FB102 to its immunology pipeline, with the upcoming Phase II celiac disease data the first test of the asset's potential beyond Vyvgart.
Scrip - July 27, 2026
Argenx's $2.2bn acquisition of Forte Biosciences adds anti-CD122 antibody FB102 to its immunology pipeline, with the upcoming Phase II celiac disease data the first test of the asset's potential beyond Vyvgart.
Scrip - July 27, 2026
The Generics Bulletin Top 50, Part One: The Big Three No More
In the first part of this year’s Generics Bulletin Top 50, we find out which one of the traditional big three off-patent companies has been pushed off the winner’s podium this year – and how far they have fallen down the top ten.
Generics Bulletin - July 27, 2026
In the first part of this year’s Generics Bulletin Top 50, we find out which one of the traditional big three off-patent companies has been pushed off the winner’s podium this year – and how far they have fallen down the top ten.
Generics Bulletin - July 27, 2026
CareDx CEO On Precision Diagnostics Pivot, Oncology Expansion
CareDx CEO John Hanna details the twin deals — a $171.2m lab products divestiture and the up-to-$260m Naveris buy — that recast the transplant-diagnostics firm as a molecular diagnostics company betting on reimbursed, repeat-tested oncology niches led by the Medicare-covered NavDx.
Medtech Insight - July 27, 2026
CareDx CEO John Hanna details the twin deals — a $171.2m lab products divestiture and the up-to-$260m Naveris buy — that recast the transplant-diagnostics firm as a molecular diagnostics company betting on reimbursed, repeat-tested oncology niches led by the Medicare-covered NavDx.
Medtech Insight - July 27, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European biotech at a crossroads.
Scrip - July 27, 2026
In this week's episode: Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European biotech at a crossroads.
Scrip - July 27, 2026
Finance Watch: Scribe Launches IPO, Oak Hill Going Public Via SPAC Merger
Public Company Edition: Scribe Therapeutics grossed $128.7m in the 14th biopharma IPO in the US in 2026, while Oak Hill Bio will go public by merging with RA Capital’s recent SPAC. Also, Dyne closed a $431.4m follow-on offering and Entra Bio raised $275m in a private placement.
Scrip - July 27, 2026
Public Company Edition: Scribe Therapeutics grossed $128.7m in the 14th biopharma IPO in the US in 2026, while Oak Hill Bio will go public by merging with RA Capital’s recent SPAC. Also, Dyne closed a $431.4m follow-on offering and Entra Bio raised $275m in a private placement.
Scrip - July 27, 2026
MapLight’s ZEPHYR Trial Hits Endpoints In Schizophrenia, But Investors Want To See More
The company reported cognitive improvement in the pivotal Phase II trial of ML-007C-MA and plans a second study in schizophrenia, while a Phase II trial in Alzheimer’s psychosis is ongoing.
Scrip - July 27, 2026
The company reported cognitive improvement in the pivotal Phase II trial of ML-007C-MA and plans a second study in schizophrenia, while a Phase II trial in Alzheimer’s psychosis is ongoing.
Scrip - July 27, 2026
With Forte, Argenx Returns To Pipeline-In-A-Product Playbook
The company made its biggest acquisition to date with the acquisition of Forte, which brings argenx a future pipeline pillar to lean on beyond Vyvgart and empasiprubart.
Scrip - July 27, 2026
The company made its biggest acquisition to date with the acquisition of Forte, which brings argenx a future pipeline pillar to lean on beyond Vyvgart and empasiprubart.
Scrip - July 27, 2026
AstraZeneca’s New Breast Cancer Drug Could Be Test Case For MFN Pricing
CEO Pascal Soriot said demands for price rises in Europe were “not unreasonable” as the company kept up its healthy growth in the second quarter.
Scrip - July 27, 2026
CEO Pascal Soriot said demands for price rises in Europe were “not unreasonable” as the company kept up its healthy growth in the second quarter.
Scrip - July 27, 2026
Zevra Europe Entry Plans For Neimann-Pick Drug Put On Hold
The US firm is appealing a CHMP negative opinion on its Niemann-Pick disease type C therapy Meplyffa, stalling having hit a stumbling block in its efforts to enter a market which is larger than the US, where the ultra-rare lysosomal storage disorder drug is already approved.
Scrip - July 27, 2026
The US firm is appealing a CHMP negative opinion on its Niemann-Pick disease type C therapy Meplyffa, stalling having hit a stumbling block in its efforts to enter a market which is larger than the US, where the ultra-rare lysosomal storage disorder drug is already approved.
Scrip - July 27, 2026
AstraZeneca Trial Wobbles Continue With Claudin 18.2 ADC Hit And Miss
A split CLARITY-Gastric01 readout gives AstraZeneca the first survival win for a CLDN18.2 ADC, but the PFS miss leaves room for rivals closing in on the same indication.
Scrip - July 27, 2026
A split CLARITY-Gastric01 readout gives AstraZeneca the first survival win for a CLDN18.2 ADC, but the PFS miss leaves room for rivals closing in on the same indication.
Scrip - July 27, 2026
Argenx To Buy Forte Biosciences For $2.2bn, Adds Clinical-Stage CD122 Autoimmune Asset
Argenx's $2.2bn acquisition of Forte Biosciences adds anti-CD122 antibody FB102 to its immunology pipeline, with the upcoming Phase II celiac disease data the first test of the asset's potential beyond Vyvgart.
Scrip - July 27, 2026
Argenx's $2.2bn acquisition of Forte Biosciences adds anti-CD122 antibody FB102 to its immunology pipeline, with the upcoming Phase II celiac disease data the first test of the asset's potential beyond Vyvgart.
Scrip - July 27, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European biotech at a crossroads.
Scrip - July 27, 2026
In this week's episode: Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European biotech at a crossroads.
Scrip - July 27, 2026
Boston Scientific Halts Enroute TCAR Systems Over Arterial Sheath Issue
Boston Scientific is telling customers to stop using Enroute Transcarotid Neuroprotection System and Enroute Transcarotid Neuroprotection System Plus. The devices, which help prevent stroke during treatment of carotid artery disease, may come apart during use.
Medtech Insight - July 27, 2026
Boston Scientific is telling customers to stop using Enroute Transcarotid Neuroprotection System and Enroute Transcarotid Neuroprotection System Plus. The devices, which help prevent stroke during treatment of carotid artery disease, may come apart during use.
Medtech Insight - July 27, 2026
FDA Approves Colorectal Cancer Blood Test From Freenome And Abbott
The US Food and Drug Administration has approved SimpleScreen CRC, a blood-based colorectal cancer screening test developed by Freenome that Abbott will exclusively commercialize in the US for average-risk adults aged 45 and older. The test detects cell-free DNA signals linked to colorectal cancer.
Medtech Insight - July 27, 2026
The US Food and Drug Administration has approved SimpleScreen CRC, a blood-based colorectal cancer screening test developed by Freenome that Abbott will exclusively commercialize in the US for average-risk adults aged 45 and older. The test detects cell-free DNA signals linked to colorectal cancer.
Medtech Insight - July 27, 2026
Women’s Oncology Market Expected To Reach $110Bn By 2030, Gynecologic Cancers Remain Underfunded
A new PwC report finds women's oncology heading toward $110bn by 2030, yet ovarian and endometrial cancers receive a fraction of breast cancer's NIH funding. Liquid biopsy, AI screening tools, and $6.5bn in private investment aim to close the gap.
Medtech Insight - July 27, 2026
A new PwC report finds women's oncology heading toward $110bn by 2030, yet ovarian and endometrial cancers receive a fraction of breast cancer's NIH funding. Liquid biopsy, AI screening tools, and $6.5bn in private investment aim to close the gap.
Medtech Insight - July 27, 2026
German Medtech Innovation Decision Signals A Crack In Industry-Government ‘Dialog’
Germany’s medtech industry said it is frustrated by outgoing health minister Warken’s last-minute decision to limit temporary reimbursement and access for new diagnostic and treatment methods (NUB). Spectaris’ medtech head Marcus Kuhlmann criticized the purely money saving initiative.
Medtech Insight - July 27, 2026
Germany’s medtech industry said it is frustrated by outgoing health minister Warken’s last-minute decision to limit temporary reimbursement and access for new diagnostic and treatment methods (NUB). Spectaris’ medtech head Marcus Kuhlmann criticized the purely money saving initiative.
Medtech Insight - July 27, 2026
WHO Names First Medtech Regulators Ready For Listed Authority Status
The World Health Organization is expanding its framework for recognizing trusted regulators into medtech, which it hopes will foster global regulatory cooperation.
Medtech Insight - July 27, 2026
The World Health Organization is expanding its framework for recognizing trusted regulators into medtech, which it hopes will foster global regulatory cooperation.
Medtech Insight - July 27, 2026
Acute Care AI Pioneer Viz.ai Takes First Step Into Chronic Brain Disease
Viz.ai is expanding beyond acute care into neurodegenerative disease, partnering with Cortechs.ai to bring quantitative brain MRI analysis into its 2,000-hospital network — with MS as the entry point and broader ambitions to follow.
Medtech Insight - July 27, 2026
Viz.ai is expanding beyond acute care into neurodegenerative disease, partnering with Cortechs.ai to bring quantitative brain MRI analysis into its 2,000-hospital network — with MS as the entry point and broader ambitions to follow.
Medtech Insight - July 27, 2026
CareDx CEO On Precision Diagnostics Pivot, Oncology Expansion
CareDx CEO John Hanna details the twin deals — a $171.2m lab products divestiture and the up-to-$260m Naveris buy — that recast the transplant-diagnostics firm as a molecular diagnostics company betting on reimbursed, repeat-tested oncology niches led by the Medicare-covered NavDx.
Medtech Insight - July 27, 2026
CareDx CEO John Hanna details the twin deals — a $171.2m lab products divestiture and the up-to-$260m Naveris buy — that recast the transplant-diagnostics firm as a molecular diagnostics company betting on reimbursed, repeat-tested oncology niches led by the Medicare-covered NavDx.
Medtech Insight - July 27, 2026
Reckitt Taps Durex Brand Equity For OTC Sildenafil Launch
As the OTC ED shelf continues to grow, Reckitt is wagering that the Durex name gives it a differentiation rivals cannot easily replicate.
HBW Insight - July 27, 2026
As the OTC ED shelf continues to grow, Reckitt is wagering that the Durex name gives it a differentiation rivals cannot easily replicate.
HBW Insight - July 27, 2026
Niagen Bioscience Adds External Research Chief
Abhijit Kale oversees firm’s network of academic and clinical research collaborations while helping shape scientific research strategy.
HBW Insight - July 27, 2026
Abhijit Kale oversees firm’s network of academic and clinical research collaborations while helping shape scientific research strategy.
HBW Insight - July 27, 2026
‘Not New Anymore’: EMA Moves Biosimilars Closer To Generic-Drug Review Model
As confidence in biosimilars grows, the European Medicines Agency is testing whether less complex marketing applications for such products can be reviewed with fewer regulatory resources, potentially freeing up assessment teams for other medicines.
Generics Bulletin - July 27, 2026
As confidence in biosimilars grows, the European Medicines Agency is testing whether less complex marketing applications for such products can be reviewed with fewer regulatory resources, potentially freeing up assessment teams for other medicines.
Generics Bulletin - July 27, 2026
Dr Reddy’s Semaglutide Woes Ripple Through Partners, CEO Vows Comeback
With "tens of partners" globally, Dr Reddy’s semaglutide supply challenges could potentially have a wider impact if the firm isn’t back in the market by November as anticipated. Partner Aspen has already flagged delays, and a Sandoz Canada supply commitment also hangs on a timely restart.
Generics Bulletin - July 27, 2026
With "tens of partners" globally, Dr Reddy’s semaglutide supply challenges could potentially have a wider impact if the firm isn’t back in the market by November as anticipated. Partner Aspen has already flagged delays, and a Sandoz Canada supply commitment also hangs on a timely restart.
Generics Bulletin - July 27, 2026
The Eyes Have It! FDA Finally Approves Outlook’s Ophthalmic Bevacizumab
Outlook Therapeutics has set out initial launch plans for its Lytenava ophthalmic bevacizumab product after finally winning approval from the US FDA.
Generics Bulletin - July 27, 2026
Outlook Therapeutics has set out initial launch plans for its Lytenava ophthalmic bevacizumab product after finally winning approval from the US FDA.
Generics Bulletin - July 27, 2026
Par Seizes First-Mover Advantage In Janumet XR Generics
Par Health has launched the first and currently only US Food and Drug Administration-approved generic version of Merck & Co’s Janumet XR (sitagliptin/metformin hydrochloride) extended-release tablets in the US, opening generic competition for the extended-release diabetes therapy shortly after agree
Generics Bulletin - July 27, 2026
Par Health has launched the first and currently only US Food and Drug Administration-approved generic version of Merck & Co’s Janumet XR (sitagliptin/metformin hydrochloride) extended-release tablets in the US, opening generic competition for the extended-release diabetes therapy shortly after agree
Generics Bulletin - July 27, 2026
The Generics Bulletin Top 50, Part One: The Big Three No More
In the first part of this year’s Generics Bulletin Top 50, we find out which one of the traditional big three off-patent companies has been pushed off the winner’s podium this year – and how far they have fallen down the top ten.
Generics Bulletin - July 27, 2026
In the first part of this year’s Generics Bulletin Top 50, we find out which one of the traditional big three off-patent companies has been pushed off the winner’s podium this year – and how far they have fallen down the top ten.
Generics Bulletin - July 27, 2026
Peer Groups, Not Performance: What Really Drives Large Pharma CEO Pay
CEOs of $10bn–$40bn pharma companies averaged $14.9m in 2025, a 36% discount to the $23.1m big pharma mean. But strip out the non-US firms and the gap nearly closes: the discount is mostly geography, with US chiefs paid up to four times their Japanese and European peers at similar-sized companies.
In Vivo - July 27, 2026
CEOs of $10bn–$40bn pharma companies averaged $14.9m in 2025, a 36% discount to the $23.1m big pharma mean. But strip out the non-US firms and the gap nearly closes: the discount is mostly geography, with US chiefs paid up to four times their Japanese and European peers at similar-sized companies.
In Vivo - July 27, 2026